Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...

Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...

Changes to serum proteins could be behind the debilitating condition known as long COVID. The findings, published in the journal Science, could pave the way for diagnosing and treating the disease.

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests. For many people, covid is an illness that blusters in and out of our lives as cases ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...